CHAPTER -1

INTRODUCTION ABOUT THE ORGANIZTION AND

INDUSTRY

1.1 Organisation Overview

• Nucleibio Scientific India Ltd (hereafter “Nucleibio” or “the Company”) an

Indian company operating in the life-sciences, research, pharmaceutical
instrumentation and laboratory equipment supply sector. On its website the
Company describes itself as:
• “Bridging the gap between the world’s leading innovative research and
laboratory equipment manufacturersand customers to improve human life.”
It offers research and development (R&D) and quality control instrumentation
solutions to various industries including pharmaceuticals, life-
sciences/biotechnology, chemical engineering, food & beverages, automotive,
and government research institutions.

Some key details:

• It supplies high-quality and cutting-edge instruments—from basic laboratory

equipment through advanced systems used in drug manufacturing and testing.
• It offers installation & setup services, maintenance & calibration, repair,
customised solutions, training & support, regulatory-compliance consulting,
inventory/procurement support, spare-parts supply, and post-sales service.
• The Company serves a wide range of industries: research institutes government
organizations; chemistry/petrochemistry/chemical engineering; life
sciences/biotechnology; food & beverages; automotive; pharmaceutical
industries.
• The Company states it was “Established in 2018 by industry experts with 15+
years of combined experience in Pharmaceuticals, Research, and Biopharma”
and claims “55+ years experience in the industry”.
 • Its mission tagline: “Your Research, Our Priority.”
Thus, Nucleibio plays the role of a specialist instrumentation & service provider in the
Indian life-sciences / pharmaceutical / laboratory ecosystem, acting as a bridge between
global instrument manufacturers and the local Indian-market customers (both industry
and research-institutes).

1.2 Mission, Vision, Values:

While the Company website provides somewhat limited explicit text around
vision/values, we can infer the following:

Mission
• “Your Research, Our Priority.” indicates the Company aims to prioritise its
customers’ research needs by providing state-of-the-art instrumentation and
support.
• It emphasises “Bridging the gap between the world’s leading innovative
research and laboratory equipment manufacturers and customers to improve
human life.”
Thus, mission: to enable research & quality control via world-class
instrumentation and service support.

Vision (inferred)
• To become a trusted partner to leading research organisations and industry,
enabling high-quality output in R&D, quality control, regulatory compliance.
• To improve human life by advancing research and instrumentation capabilities.

Values (inferred from service list)

• Customer focus: aligning advanced technologies with customer needs.
• Innovation: providing “state-of-the-art R&D and quality control tools.”
• Quality & Compliance: the services include calibration/maintenance and
regulatory-compliance consulting.
• Long-term partnerships: post-sales support, inventory & procurement support,
spare parts supply.
• Coverage across multiple industries: flexibility, breadth.
1.3 Products, Services and Business Model

Products:
Nucleibio supplies a variety of laboratory and process-instrumentation equipment.
Although specific catalogue details are not deeply outlined on the publicly accessible
pages, we know they supply from basic lab equipment up to advanced systems used in
drug manufacturing & testing. Some likely categories include: analytical instruments
(e.g., spectroscopy, chromatography), lab consumables, quality-control
instrumentation, calibration equipment, upstream/downstream research-tools for
biotechnology & life‐sciences.

Services:
Their services accompany the products, and include:
• Installation & setup of equipment, ensuring proper calibration and performance.
• Maintenance & calibration services (routine/emergency) to keep equipment
operational and compliant.
• Repair services to minimise downtime of instrumentation.
• Customised solutions: bespoke setups for unique pharmaceutical processes or
specialised testing and production requirements.
• Training & support: training of staff on correct operation & maintenance;
technical support available.
• Regulatory compliance consulting: helping clients ensure instruments comply with
standards, e.g., GMP, FDA, ISO.
• Inventory management & procurement support: assisting clients to manage
instrument inventory and procurement efficiently.
• Spare parts supply and post-sales support: ensuring longevity and performance of
equipment.

Business Model:
• Nucleibio appears to act as a distributor/partner for internationally reputed
instrumentation manufacturers (i.e., they supply products from globally reputed
manufacturers) and serves as the local interface for customers in India (and
perhaps neighbouring regions) who need instrumentation plus services.
• Revenue is derived from sales of instrumentation plus services (installation,
calibration, maintenance, training) and spare‐parts.
 • It may also derive income from customised solution design, regulatory
consulting and procurement/inventory services.

• The value proposition is: provide reliable instruments + end-to-end support,

tailored to research and industrial clients, thereby reducing downtime risk,
ensuring compliance, and enabling quality output.
• Given the industries served (pharma, biotech, food, chemicals, automotive), the
model leverages cross-industry instrumentation needs and service contracts.

1.4 Industry Context – India & Global:

To understand Nucleibio’s operating context, it is essential to examine the broader
industry of life-sciences tools, laboratory instrumentation, analytical instruments, and
the pharmaceutical/biotech sector in India and globally.

1.4.1 Indian Pharmaceutical & R&D Market:

• The Indian pharmaceutical manufacturing market was estimated at USD 17.79
billion in 2023 and is forecast to grow at a CAGR of 10.5% from 2024 to 2030.
• For FY 2023-24 the Indian pharmaceutical market (domestic + exports) is
valued at USD 50 billion, with domestic consumption at USD 23.5 billion and
exports at USD 26.5 billion.
• India ranks third globally in volume of pharmaceutical production. Thus,
the pharmaceutical sector in India is substantial and growing – creating demand
not only for drugs and APIs, but also for laboratory and process instrumentation,
R&D services, quality control equipment and maintenance.

1.4.2 Life Sciences Tools & Analytical Instruments Market in

India:
• The India Analytical Instruments Market was valued at USD 942.86 million in
2024 and is projected to reach USD 1,316.67 million by 2030 (CAGR ~6.01 %).
• The India Life-Sciences Tools Market has been estimated at USD 14.44 billion
in FY 2023 and is projected to reach USD 33.76 billion by FY 2031, growing at
a CAGR of ~11.22%.
These figures indicate strong growth opportunities in the instrumentation / tools
segment that Nucleibio participates in.
1.4.3 Global Trends & Relevance:

Globally, the life‐sciences/biotech sector is evolving rapidly: genomics, proteomics,

next‐generation sequencing, cell‐based assays, personalised medicine are driving
demand for advanced instruments and solutions. This creates opportunity for companies
offering high‐end instrumentation, service support, and customised solutions. In India,
government policies (such as those encouraging R&D, innovation, domestic
manufacturing of medical/diagnostic devices) also contribute to market growth.

1.4.4 Industry Drivers:

Several key factors drive growth in the instrumentation/services sector:
• Expansion of pharmaceutical manufacturing (domestic and contract
manufacturing) increases demand for quality-control, process instrumentation
and laboratory analytics.
• Growth of biotech, life-sciences research (academic + industry) needing
advanced equipment.
• Rising regulatory and compliance demands (GMP, FDA, ISO) forcing
companies to invest in higher-standard instrumentation and
calibration/maintenance services.
• Government support and incentives for “Make in India”, domestic
manufacturing and instrumentation - enabling growth of supporting ecosystems.
• Technological advancements: automation, connectivity (IoT), data analytics,
remote monitoring, digitalisation of labs – requiring newer instruments and

support services.

1.4.5 Industry Challenges:

However, the industry also faces certain challenges:
• High capital cost of advanced instrumentation and long replacement/upgrade
cycles.
• Skill gap: operation, maintenance, calibration require trained personnel; after-
sales service quality becomes key.
• Rapid technological change — instruments may become obsolete quickly or
require software upgrades.
• Regulatory and compliance pressure: adhering to multiple standards can raise
cost and complexity.
• Competition from global instrument suppliers, and price sensitivity in emerging
markets such as India.
• Supply-chain/logistics risks (import duties, spare parts availability, calibration
traceability).
1.5 How Nucleibio Fits in the Industry:
Given the context above, Nucleibio occupies a strategic niche. Key points of fit:
• It serves multiple industries (pharma, biotech, chemicals, food, automotive)
thereby diversifying its customer base and reducing dependence on a single
vertical.
• By partnering with internationally reputed instrument manufacturers and
supplying such equipment locally, it addresses the gap between global
innovation and the Indian customer market (“bridging the gap”).
• Its strong offering of services (installation, calibration, maintenance, repair,
regulatory compliance consulting) adds value beyond simply equipment sales
— addressing one of the industry challenges (after‐sales support and
calibration).
• Because the Indian instrumentation market is growing (see section 1.4.2),
Nucleibio is positioned to leverage this growth.
• The breadth of industries served means that as sectors such as biotech, pharma,
food testing expand, the demand for instrumentation and services increases –
giving Nucleibio an opportunity to grow.
• The Company’s value proposition (customer focus, long-term support,
customised solutions) aligns with key success factors in the
instrumentation/services business in India (skill, service quality, compliance).
• The fact that it emphasises regulatory compliance (GMP, FDA, ISO) positions
it well in the highly regulated pharmaceutical/biotech domain.

1.6 Key Opportunities and Strategic Considerations:

Some of the major opportunities for Nucleibio:
• Capitalising on the growth of the Indian pharmaceutical industry (expansion of
manufacturing, quality-control labs, contract manufacturing organisations)
means more demand for instrumentation & services.
• Growth of life-sciences research in India (academic & commercial) increases
demand for advanced lab tools, consumables, and service support.
• Increasing focus on R&D and innovation (supported by policy) means more
advanced instrumentation will be needed (genomics, proteomics, cell-biology,
analytics).
• Potential to expand into newer geographies or export markets, or provide
differentiated bundled service-instrumentation packages.
• Upgrading/upscaling service offerings: predictive maintenance, IoT‐enabled
instrumentation service, data analytics, training.
Strategic considerations / challenges:
• Staying ahead in terms of technology: must partner with the right instrument
manufacturers, ensure the product offering remains current.
• Ensuring high service quality and maintaining qualified personnel for
installation, calibration, repair and compliance consulting.
• Managing supply chain (import of instruments/spare‐parts), calibration
traceability and service turnaround time.
• Differentiation in a competitive market (other instrument-suppliers, large
multinational companies).
• Pricing pressures and cost management, particularly for customers in price‐
sensitive segments.

• Building client relationships and trust, especially in highly regulated industries

(pharma/biotech) where downtime or non-compliance can be costly customers.